
Takeda Achieves Key Regulatory Milestone as FDA Accepts NDA and Grants Priority Review for Oveporexton
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 Takeda today announced that the U.S. Food and Drug Administration (FDA) accepted its New…












